| | | | | Results of Plaque Reduction Neutralization Tests [1] |
|---|
| | Virus |
|---|
| Immune Serum | VSNJ | VSI | COC | PIRY | CHP | ISF |
|---|
|
| | * Reciprocal of highest serum dilution producing >95% plaque inhibition. | | ** Prepared in a guinea pig sequentially inoculated with Piry Chandipura, Indiana, New Jersey, and Cocal viruses. | | Note: All immune sera prepared in guinea pigs receiving 2-5 subcutaneous injections of live virus at 14-day intervals. | | VSNJ | 10240 * | <10 | <10 | <10 | <10 | <10 | | VSI | <10 | 327680 | 320 | <10 | <10 | <10 | | COC | <10 | 160 | 5120 | <10 | <10 | <10 | | VSA | <10 | 20 | 20 | <10 | <10 | <10 | | PIRY | <10 | <10 | <10 | 10240 | <10 | <10 | | CHP | <10 | <10 | <10 | <10 | 10240 | <10 | | ISF | <10 | <10 | <10 | <10 | <10 | 2560 | | Group | | | | | | | VSV ** | 640 | 2560 | 160 | 5120 | 1280 | 40 |
| | | | Results of Complement Fixation Tests [2] |
|---|
| | Antibody |
|---|
| | ISF | ISF GP | CHP | Piry |
|---|
| Antigen | MIAF | Serum | MIAF | IMS |
|---|
|
| | Antibody titer/antigen titer | | Isfahan | 1024/1024 | 256/256 | 16/16 | 8/4 | | Chandipura | | | | | (I 653514) | 64/256 | 32/16 | 256/1024 | 16/64 | | Chandipura | | | | | (IbAn 9978) | 32/256 | 32/16 | 256/1024 | 16/16 | | Piry | 64/16 | 8/4 | 16/4 | 512/64 | | Flanders | | | | | (Control) | 4/<4 | <4/<4 | <4/<4 | <4/<4 |
| | In other CF tests, ISF antigen (8 units) and guinea pig antiserum were negative when tested against VSNJ (homologous serum titer = 128), VSI (2048) and COC (128) viruses. Also, ISF antigen did not react with VSA antiserum (200) [1] . | | |
|
